Novartis-Propeller near commercial launch. 5 biz models for MSK.

Issue 051.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 55 percent open rate. Here's what's happening this week:

Starting to see some smart takes on how the pandemic will change healthcare and digital health. If you haven't read these yet, dig in to John Moore's Chilmark Research site and this one (from a few weeks ago) over at Lisa Suennen's VentureValkyrie blog.
Seems like each week there is an update on Roche's VR digital therapeutic for autism. The company announced it was partnering with Harman, a division of Samsung, to build the technology components of the offering. They hint it may lead to digital products for other conditions, too.
CSL Behring, a large biotech company focused on rare diseases like hemophilia, von Willebrand disease (VWD), primary immunodeficiency (PID), hereditary angioedema (HAE),

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Novartis-Propeller near commercial launch. 5 biz models for MSK.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.